Coherus BioSciences (NASDAQ: CHRS) has scheduled its first quarter 2025 financial results announcement for Monday, May 12, 2025, after market close. The company will host a conference call and webcast at 5:00 p.m. EDT on the same day, where management will discuss the financial results and provide a business update. Investors can pre-register for the conference call to receive dial-in information and a personal PIN. A webcast will be available live and archived on the company's investor relations website. The Q1 2025 financial results press release and related materials will be accessible at https://investors.coherus.com before the conference call.
Coherus BioSciences (NASDAQ: CHRS) ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per lunedì 12 maggio 2025, dopo la chiusura del mercato. La società terrà una conference call e una webcast alle 17:00 EDT dello stesso giorno, durante le quali la direzione discuterà i risultati finanziari e fornirà un aggiornamento sull'andamento aziendale. Gli investitori possono preregistrarsi alla conference call per ricevere le informazioni di accesso e un PIN personale. La webcast sarà disponibile in diretta e in archivio sul sito web delle relazioni con gli investitori della società. Il comunicato stampa con i risultati finanziari del Q1 2025 e i materiali correlati saranno accessibili su https://investors.coherus.com prima della conference call.
Coherus BioSciences (NASDAQ: CHRS) ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el lunes 12 de mayo de 2025, después del cierre del mercado. La compañía realizará una llamada conferencia y una transmisión web a las 5:00 p.m. EDT del mismo día, donde la dirección discutirá los resultados financieros y proporcionará una actualización del negocio. Los inversores pueden preinscribirse para la llamada conferencia y recibir la información de acceso y un PIN personal. La transmisión web estará disponible en vivo y archivada en el sitio web de relaciones con inversores de la empresa. El comunicado de prensa con los resultados financieros del primer trimestre de 2025 y los materiales relacionados estarán disponibles en https://investors.coherus.com antes de la llamada conferencia.
Coherus BioSciences (NASDAQ: CHRS)는 2025년 1분기 재무 실적 발표를 2025년 5월 12일 월요일 장 마감 후에 예정하고 있습니다. 회사는 같은 날 오후 5시 EDT에 컨퍼런스 콜과 웹캐스트를 개최하며, 경영진이 재무 실적을 논의하고 사업 현황을 업데이트할 예정입니다. 투자자들은 컨퍼런스 콜에 사전 등록하여 전화 접속 정보와 개인 PIN을 받을 수 있습니다. 웹캐스트는 회사 투자자 관계 웹사이트에서 실시간 및 아카이브로 제공됩니다. 2025년 1분기 재무 실적 보도자료 및 관련 자료는 컨퍼런스 콜 전에 https://investors.coherus.com에서 확인할 수 있습니다.
Coherus BioSciences (NASDAQ : CHRS) a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le lundi 12 mai 2025, après la clôture du marché. La société organisera une conférence téléphonique et une webdiffusion à 17h00 EDT le même jour, au cours desquelles la direction discutera des résultats financiers et fournira une mise à jour sur l'activité. Les investisseurs peuvent s'inscrire à l'avance à la conférence téléphonique pour recevoir les informations d'accès et un code PIN personnel. La webdiffusion sera disponible en direct et en archive sur le site des relations investisseurs de la société. Le communiqué de presse des résultats financiers du T1 2025 et les documents associés seront accessibles sur https://investors.coherus.com avant la conférence téléphonique.
Coherus BioSciences (NASDAQ: CHRS) hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für Montag, den 12. Mai 2025, nach Börsenschluss, geplant. Das Unternehmen wird am selben Tag um 17:00 Uhr EDT eine Telefonkonferenz und einen Webcast abhalten, bei denen das Management die Finanzergebnisse besprechen und ein Geschäftsupdate geben wird. Investoren können sich vorab für die Telefonkonferenz registrieren, um Einwahlinformationen und eine persönliche PIN zu erhalten. Ein Webcast wird live und als Archiv auf der Investor-Relations-Website des Unternehmens verfügbar sein. Die Pressemitteilung zu den Finanzergebnissen des ersten Quartals 2025 und die dazugehörigen Materialien werden vor der Telefonkonferenz unter https://investors.coherus.com zugänglich sein.
Positive
None.
Negative
None.
REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May 12, 2025. Starting at 5:00 p.m. EDT on May 12, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call.
Conference Call Information
When: Monday, May 12, 2025, starting at 5:00 p.m. Eastern Daylight Time
The press release with the first quarter 2025 financial results and related materials will be available at https://investors.coherus.com before the start of the conference call.
A live and archived webcast will be available on the “Investors” section of the Coherus website at https://investors.coherus.com/events-presentations.
Please dial in 15 minutes early to ensure a timely connection to the call.
Disclosure Information
Coherus uses the https://investors.coherus.com website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
About Coherus
Coherus is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), growing revenues and a promising pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Our strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as our partners’, driving sales multiples and synergies from proprietary combinations.
Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. CHS-114 is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1 studies in patients with advanced solid tumors, including head and neck squamous cell carcinoma and gastric cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in multiple Phase 1/2 and Phase 2 studies in patients with advanced solid tumors including non-small cell lung cancer and in hepatocellular carcinoma.
For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit www.loqtorzi.com.
When will Coherus (CHRS) release its Q1 2025 earnings?
Coherus BioSciences will release its Q1 2025 earnings after market close on Monday, May 12, 2025.
What time is the Coherus (CHRS) Q1 2025 earnings call?
The Coherus Q1 2025 earnings conference call is scheduled for Monday, May 12, 2025, at 5:00 p.m. EDT.
How can I access Coherus (CHRS) Q1 2025 earnings call?
Investors can pre-register for the call through the registration link provided by Coherus, or access the webcast at https://edge.media-server.com/mmc/p/rj9hzxof.
Where can I find Coherus (CHRS) Q1 2025 earnings materials?
The Q1 2025 earnings press release and related materials will be available at https://investors.coherus.com before the conference call.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
